NSCLC patient-derived xenografts perpetuating tumor-associated, tumor-reactive T cells that respond to immunotherapy but do not cause GVHD in host mice

نویسندگان

چکیده

Abstract Non-small cell lung cancer (NSCLC) is the leading cause of malignancy-related deaths worldwide. We wished to overcome a current major limitation PDX modeling, by providing autologous human T cells suitable for immunotherapy responses, but notably, without graft versus host disease (GVHD). have developed PDXs from NSCLC implanting surgically resected patient tumors subcutaneously in NOD scid gamma (NSG) mice. used metastatic model test potential therapeutic efficacy novel molecule, anti-human-CD3ɛ monovalent Fab fragment (Mono-OKT3-Fab) and compared tumor growth results with anti-human PD-L1 therapy. Overall engraftment rate unique, primary was 52%. Over multiple passages vivo, retained expression tumor-matched NSCLC-diagnostic pathological markers. Moreover, primary-tumor-associated were present passaged mice producing any signs GVHD. Immunotherapy showed significant response PDL-1+ tumor, consistent functional tumor-specific passaging our system. In contrast, control experiments using patient-matched PBMCs vigorous GVHD presence or absence co-transplanted tumor; this demonstrated that non-tumor-associated lymphocytes these patients capable xenoreaction, even though tumor-associated not. observed PDX-NSG treated either modality significantly reduced burden increased survival over control-Ig-treated Overall, study shows implanted NSG resected-NSCLC retain sufficient preclinical evaluation cell-targeting immunotherapies. NIH, National Cancer Institute, IOTN(U01 CA244314) NIAID, R01 AI097187 Mizzou Start-up funds

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Tumor-reactive T-Cells Accumulate in Lung Cancer Tissues but Fail to Respond Due to Tumor Cell-derived Factor1

The purpose of this study was to elucidate a possible immune response to tumor cells mediated by tumor-infiltrating lymphocytes (TIL) in lung cancer. In flow cytometry, the majority of T-cells of TIL were CD45RA", CD45RO*, and CDw29h'«h, and expressed HLA-DR. The expression of interleukin 2 receptor ßchain increased in both CD4* and <'IMP TIL compared with both types of T-cells in peripheral ...

متن کامل

Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.

The purpose of this study was to elucidate a possible immune response to tumor cells mediated by tumor-infiltrating lymphocytes (TIL) in lung cancer. In flow cytometry, the majority of T-cells of TIL were CD45RA-, CD45RO+, and CDw29high, and expressed HLA-DR. The expression of interleukin 2 receptor beta chain increased in both CD4+ and CD8+ TIL compared with both types of T-cells in peripheral...

متن کامل

Cancer Therapy: Preclinical InhibitionofMEKandPI3K/mTORSuppressesTumorGrowth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

Purpose: Gene mutations along the Ras pathway (KRAS,NRAS, BRAF, PIK3CA) occur in approximately 50% of colorectal cancers (CRC) and correlate with poor response to anti–EGF receptor (EGFR) therapies. We assessed the effects of mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) and phosphoinositide 3-kinase (PI3K)/mTOR inhibitors, which neutralize the major R...

متن کامل

Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.

Preclinical models often fail to capture the diverse heterogeneity of human malignancies and as such lack clinical predictive power. Patient-derived tumor xenografts (PDX) have emerged as a powerful technology: capable of retaining the molecular heterogeneity of their originating sample. However, heterogeneity within a tumor is governed by both cell-autonomous (e.g., genetic and epigenetic hete...

متن کامل

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

PURPOSE Gene mutations along the Ras pathway (KRAS, NRAS, BRAF, PIK3CA) occur in approximately 50% of colorectal cancers (CRC) and correlate with poor response to anti-EGF receptor (EGFR) therapies. We assessed the effects of mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) and phosphoinositide 3-kinase (PI3K)/mTOR inhibitors, which neutralize the major R...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Immunology

سال: 2023

ISSN: ['1550-6606', '0022-1767']

DOI: https://doi.org/10.4049/jimmunol.210.supp.230.12